И. П. Никишина
A5091020794- Autoimmune and Inflammatory Disorders Research
- Adolescent and Pediatric Healthcare
- Inflammasome and immune disorders
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Systemic Sclerosis and Related Diseases
- Kawasaki Disease and Coronary Complications
- Spondyloarthritis Studies and Treatments
- Immunodeficiency and Autoimmune Disorders
- Acute Lymphoblastic Leukemia research
- Liver Diseases and Immunity
- Ocular Diseases and Behçet’s Syndrome
- Human Health and Disease
- Child and Adolescent Health
- Heterotopic Ossification and Related Conditions
- Childhood Cancer Survivors' Quality of Life
- Inflammatory Myopathies and Dermatomyositis
- Sarcoidosis and Beryllium Toxicity Research
- Osteomyelitis and Bone Disorders Research
- Medical Imaging and Pathology Studies
- Orthopedic Infections and Treatments
- Eosinophilic Disorders and Syndromes
- Family and Disability Support Research
- Hip disorders and treatments
- IL-33, ST2, and ILC Pathways
VA Nasonova Scientific Research Institute of Rheumatology
2016-2025
Cincinnati Children's Hospital Medical Center
2018
Sydney Children's Hospital
2018
University of Cincinnati
2018
Great Ormond Street Hospital
2014
University College London
2014
Queen Mary University of London
2013
Russian Academy of Sciences
2001-2013
Academy of Medical Sciences
2001
Objective To evaluate the interleukin-6 receptor inhibitor tocilizumab for treatment of patients with polyarticular-course juvenile idiopathic arthritis (pcJIA). Methods This three-part, randomised, placebo-controlled, double-blind withdrawal study ( NCT00988221 ) included who had active pcJIA ≥6 months and inadequate responses to methotrexate. During part 1, received open-label every 4 weeks (8 or 10 mg/kg body weight (BW) <30 kg; 8 BW ≥30 kg). At week 16, ≥JIA-American College...
<h3>Objective</h3> To evaluate genetic, demographic and clinical features in patients with cryopyrin-associated periodic syndrome (CAPS) from the Eurofever Registry, a focus on genotype-phenotype correlations predictive disease severity markers. <h3>Methods</h3> A web-based registry retrospectively collected data CAPS. Experts independently validated all cases. Patients carrying <i>NLRP3</i> variants germline-mutation-negative were included. <h3>Results</h3> 136 analysed. The median age at...
This report aims to determine the safety, pharmacokinetics (PK) and efficacy of subcutaneous golimumab in active polyarticular-course juvenile idiopathic arthritis (polyJIA).In this three-part randomised double-blinded placebo-controlled withdrawal trial, all patients received open-label (30 mg/m2 body surface area; maximum: 50 mg/dose) every 4 weeks together with weekly methotrexate during Part 1 (weeks 0-16). Patients at least 30% improvement per American College Rheumatology Criteria for...
Abstract Objective To investigate the safety and efficacy of subcutaneous tocilizumab (SC-TCZ) treatment in a long-term extension (LTE) clinical trials polyarticular or systemic juvenile idiopathic arthritis (pJIA sJIA). Methods Patients with pJIA sJIA from two open-label, 52-week phase 1b core SC-TCZ who had adequate response per investigator assessment entered LTE continued according to body weight–based dosing regimens until commercial availability up 5 years. Pharmacokinetics,...
Abstract Objective To investigate the proxy‐reported health‐related quality of life (HRQOL) and its determinants in patients with juvenile idiopathic arthritis (JIA). Methods In this multinational, multicenter, cross‐sectional study, HRQOL JIA was assessed through Child Health Questionnaire (CHQ) compared that healthy children similar age from same geographic area. Potential included demographic data, physician's parent's global assessments, measures joint inflammation, Childhood Assessment...
Objectives Autoinflammatory diseases cause systemic inflammation that can result in damage to multiple organs. A validated instrument is essential quantify individual patients and compare disease outcomes clinical studies. Currently, there no such tool. Our objective was develop a common autoinflammatory index (ADDI) for familial Mediterranean fever, cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated fever syndrome mevalonate kinase deficiency. Methods We...
Objective. Abatacept (ABA) has recently been proposed as second-line treatment in patients with juvenile idiopathic arthritis (JIA)–associated uveitis refractory to anti–tumor necrosis factor-α (anti-TNF) agents, but little is known about its efficacy a first-line approach. The aim of the present study was compare safety and ABA biological agent (ABA-1) that after 1 or more anti-TNF agents (ABA-2), severe JIA-related uveitis. Methods. In this multicenter study, we collected data on treated...
To describe the clinical characteristics, treatment response and genetic findings in a large cohort of patients with undefined systemic autoinflammatory diseases (SAIDs).Clinical data from SAIDs were extracted Eurofever registry, an international web-based registry that retrospectively collects information on diseases.This study included 187 patients. Seven had chronic disease course, 180 recurrent course. The median age at onset was 4.3 years. Patients 12 episodes per year, duration 4 days....
Objective To develop and validate new Juvenile Arthritis Disease Activity Score 10 (JADAS10) clinical JADAS10 (cJADAS10) cutoffs to separate the states of inactive disease (ID), minimal activity (MiDA), moderate (MoDA), high (HDA) in children with oligoarthritis rheumatoid factor–negative polyarthritis, based on subjective assessment by treating pediatric rheumatologist. Methods The definition cohort was composed 1,936 patients included multinational Epidemiology, Treatment Outcome Childhood...
Abstract Objective In an international, multicenter, double‐blind, randomized clinical trial we evaluated the short‐term (3 months) and long‐term (12 efficacy safety of 2 different doses meloxicam oral suspension compared with naproxen in children oligoarticular‐course (oligo‐course) or polyarticular‐course (poly‐course) juvenile idiopathic arthritis (JIA). Methods Children ages 2–16 years who had active oligo‐course poly‐course JIA required therapy a nonsteroidal antiinflammatory drug were...
Objective. The main objective was to determine the 2-year clinical benefit and safety of etanercept (ETN) in children with juvenile idiopathic arthritis (JIA) categories extended oligoarthritis (eoJIA), enthesitis-related (ERA), or psoriatic (PsA). Methods. CLIPPER a 96-week, phase IIIb, open-label, multicenter study. Patients eoJIA, ERA, PsA received ETN 0.8 mg/kg once weekly (50 mg max) for up 96 weeks. proportions patients reaching JIA American College Rheumatology (ACR) 30/50/70/90/100...
By the end of first decade 21st century, spondyloarthritis studies have accumulated a certain number of terms that are obsolete, but used by physicians in their everyday speech, on one hand, and great variety different definitions, other hand. In January 2014, organizational meeting Expert Group on Spondyloarthritis, Association Rheumatologists Russia, decided its primary task should be to order terminology used this area. The authors primarily collected terms, which had been already medical...
Abstract Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that caused by a mutation in the ACVR1 gene and provokes severe heterotopic ossification. Since flares of disease are associated with inflammation, it assumed JAK inhibitors can control active FOP due to blocking multiple signaling pathways.
Abstract Objective The aim of this study was to report the interim 5-year safety and effectiveness abatacept in patients with JIA PRINTO/PRCSG registry. Methods Abatacept Registry (NCT01357668) is an ongoing observational children receiving abatacept; enrolment started January 2013. Clinical sites enrolled starting or currently abatacept. Eligible were assessed for (primary end point) over 10 years. Effectiveness measured by clinical 10-joint Juvenile Arthritis Disease Activity Score...
To describe the 6-year safety and efficacy of etanercept (ETN) in children with extended oligoarticular juvenile idiopathic arthritis (eoJIA), enthesitis-related (ERA), psoriatic (PsA) METHODS: Patients who completed 2-year, open-label, phase III CLinical Study In Pediatric Etanercept for Treatment ERA, PsA, Extended Oligoarthritis (CLIPPER) were allowed to enroll its 8-year long-term extension (CLIPPER2). Children received ETN at a once-weekly dose 0.8 mg/kg, up maximum 50 mg/week. Efficacy...
The paper gives the recommendations for assessment of disease activity and functional status in patients with ankylosing spondylitis clinical practice, which have been developed by experts, taking into account international Russian experience managing these patients.
<h3>Introduction</h3> Autoinflammatory diseases can cause irreversible tissue damage due to systemic inflammation. Recently, the Disease Damage Index (ADDI) was developed. The ADDI is first instrument quantify in familial Mediterranean fever, cryopyrin-associated periodic syndromes, mevalonate kinase deficiency and tumour necrosis factor receptor-associated syndrome. aim of this study validate tool for its intended use a clinical/research setting. <h3>Methods</h3> scored on paper clinical...
Objective To evaluate the long‐term efficacy and safety of canakinumab explore prediction response in patients with systemic juvenile idiopathic arthritis (JIA) or without fever at treatment initiation. Methods At enrollment, active JIA (ages 2 to <20 years) started open‐label (4 mg/kg every 4 weeks subcutaneously). Efficacy measures included adapted American College Rheumatology (ACR) Pediatric 50/70/90 criteria, Juvenile Arthritis Disease Activity Score (JADAS), clinically inactive...
Background. Fibrodysplasia ossificans progressiva (FOP) — is an extremely rare genetic disorder with autosomal dominant type of inheritance. FOP associated a genetically determined caused by the presence specific mutation in ACVR1/ALK2 gene encoding bone morphogenetic protein receptor. clinically manifested unrestrained formation heterotopic ossifications, leading to gradual progression disability up complete immobility patient. At early age, disease can be recognized characteristic...
Abstract Pain perception is a fundamental protective mechanism that enables us to detect noxious stimuli. With focus on finding treatments for pain, the molecular mechanisms and key players involved in pain are currently under intense study. Congenital insensitivity one of rarest most unusual disorders. One reasons pure congenital absence pathogenic variants SCN9A gene, which encodes α-subunit Na v 1.7 voltage-gated sodium channel. To date, described associated with biallelic frameshifting...
Background . The management of children with systemic lupus erythematosus (SLE) is usually associated lifelong glucocorticoids administration and, thereby, high risk serious side effects, including steroid-induced diabetes. belimumab (B-lymphocyte stimulator inhibitor) significantly reduces the dose, and severity steroid therapy complications. Clinical case description patient was diagnosed SLE at age 16 years. Therapy hydroxychloroquine oral glucocorticoid a dose (methylprednisolone 56 mg...